Status Epilepticus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major status epilepticus markets reached a value of US$ 884 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,338.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.
The status epilepticus market has been comprehensively analyzed in IMARC's new report titled "Status Epilepticus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Status epilepticus (SE) refers to a medical emergency characterized by continuous or recurrent seizures that last for a prolonged period, typically longer than five minutes, or repeated seizures without returning to consciousness in between. It is a serious and life-threatening condition that requires prompt and appropriate intervention to prevent long-term complications, including brain damage, cognitive impairment, and death. The symptoms of SE can vary depending on the type of seizure and the part of the brain affected. Some of the common symptoms include convulsions, loss of consciousness, confusion, agitation, and difficulty breathing. In some cases, the signs may be more subtle and may involve only a brief loss of consciousness, muscle twitching, or repetitive movements. The diagnosis of SE includes evaluating medical history, performing a physical exam, and other additional tests such as blood tests, imaging studies (CT or MRI scans of the brain), and an electroencephalogram (EEG). The EEG is an important diagnostic tool that can confirm the presence of epileptic activity and provide information on the type and location of the seizure. Other tests may also be performed to identify the underlying cause of SE, including a lumbar puncture to evaluate for infections or cerebrospinal fluid abnormalities.
The increasing prevalence of epilepsy on account of the rising incidences of several associated risk factors, such as birth-related injuries, neurological disorders, infections, substance abuse, etc., is primarily driving the status epilepticus market. In addition to this, the widespread adoption of transcranial magnetic stimulation (TMS), a non-invasive therapy that involves the use of magnetic fields to stimulate the brain, in order to reduce the frequency and severity of seizures, is also creating a positive outlook for the market. Moreover, the escalating utilization of vagus nerve stimulation (VNS) devices as an adjunct therapy in the management of refractory status epilepticus (RSE), which is a life-threatening condition wherein seizures do not respond to first- and second-line anticonvulsant drug treatment, is further acting as a significant growth-inducing factor. Apart from this, ongoing technological advancements in electroencephalography (EEG) technology are making it easier to monitor patients with SE and adjust their treatment based on their brain activity. This, in turn, is also bolstering the market. Additionally, the introduction of various government initiatives to raise awareness about the disorder, promote research, and offer active assistance by expediting the development of better treatment options is further propelling the market growth. Besides this, the emerging popularity of second- and third-generation anti-epileptic drugs, since they are more potent and have a more favorable safety profile compared to traditional AEDs, with fewer side effects and drug interactions, is expected to drive the status epilepticus market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the status epilepticus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for status epilepticus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the status epilepticus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the status epilepticus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the status epilepticus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current status epilepticus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the status epilepticus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the status epilepticus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the status epilepticus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of status epilepticus across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with status epilepticus across the seven major markets?
What is the size of the status epilepticus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of status epilepticus?
What will be the growth rate of patients across the seven major markets?
Status Epilepticus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for status epilepticus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the status epilepticus market?
What are the key regulatory events related to the status epilepticus market?
What is the structure of clinical trial landscape by status related to the status epilepticus market?
What is the structure of clinical trial landscape by phase related to the status epilepticus market?
What is the structure of clinical trial landscape by route of administration related to the status epilepticus market?
The status epilepticus market has been comprehensively analyzed in IMARC's new report titled "Status Epilepticus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Status epilepticus (SE) refers to a medical emergency characterized by continuous or recurrent seizures that last for a prolonged period, typically longer than five minutes, or repeated seizures without returning to consciousness in between. It is a serious and life-threatening condition that requires prompt and appropriate intervention to prevent long-term complications, including brain damage, cognitive impairment, and death. The symptoms of SE can vary depending on the type of seizure and the part of the brain affected. Some of the common symptoms include convulsions, loss of consciousness, confusion, agitation, and difficulty breathing. In some cases, the signs may be more subtle and may involve only a brief loss of consciousness, muscle twitching, or repetitive movements. The diagnosis of SE includes evaluating medical history, performing a physical exam, and other additional tests such as blood tests, imaging studies (CT or MRI scans of the brain), and an electroencephalogram (EEG). The EEG is an important diagnostic tool that can confirm the presence of epileptic activity and provide information on the type and location of the seizure. Other tests may also be performed to identify the underlying cause of SE, including a lumbar puncture to evaluate for infections or cerebrospinal fluid abnormalities.
The increasing prevalence of epilepsy on account of the rising incidences of several associated risk factors, such as birth-related injuries, neurological disorders, infections, substance abuse, etc., is primarily driving the status epilepticus market. In addition to this, the widespread adoption of transcranial magnetic stimulation (TMS), a non-invasive therapy that involves the use of magnetic fields to stimulate the brain, in order to reduce the frequency and severity of seizures, is also creating a positive outlook for the market. Moreover, the escalating utilization of vagus nerve stimulation (VNS) devices as an adjunct therapy in the management of refractory status epilepticus (RSE), which is a life-threatening condition wherein seizures do not respond to first- and second-line anticonvulsant drug treatment, is further acting as a significant growth-inducing factor. Apart from this, ongoing technological advancements in electroencephalography (EEG) technology are making it easier to monitor patients with SE and adjust their treatment based on their brain activity. This, in turn, is also bolstering the market. Additionally, the introduction of various government initiatives to raise awareness about the disorder, promote research, and offer active assistance by expediting the development of better treatment options is further propelling the market growth. Besides this, the emerging popularity of second- and third-generation anti-epileptic drugs, since they are more potent and have a more favorable safety profile compared to traditional AEDs, with fewer side effects and drug interactions, is expected to drive the status epilepticus market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the status epilepticus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for status epilepticus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the status epilepticus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the status epilepticus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the status epilepticus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current status epilepticus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the status epilepticus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the status epilepticus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the status epilepticus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of status epilepticus across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of status epilepticus by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with status epilepticus across the seven major markets?
What is the size of the status epilepticus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of status epilepticus?
What will be the growth rate of patients across the seven major markets?
Status Epilepticus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for status epilepticus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the status epilepticus market?
What are the key regulatory events related to the status epilepticus market?
What is the structure of clinical trial landscape by status related to the status epilepticus market?
What is the structure of clinical trial landscape by phase related to the status epilepticus market?
What is the structure of clinical trial landscape by route of administration related to the status epilepticus market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 STATUS EPILEPTICUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 STATUS EPILEPTICUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 STATUS EPILEPTICUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 STATUS EPILEPTICUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 STATUS EPILEPTICUS - UNMET NEEDS
10 STATUS EPILEPTICUS - KEY ENDPOINTS OF TREATMENT
11 STATUS EPILEPTICUS - MARKETED PRODUCTS
11.1 List of Status Epilepticus Marketed Drugs Across the Top 7 Markets
11.1.1 Midazolam buccal - Neuraxpharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 STATUS EPILEPTICUS - PIPELINE DRUGS
12.1 List of Status Epilepticus Pipeline Drugs Across the Top 7 Markets
12.1.1 Ganaxolone - Marinus Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Midazolam autoinjector - Crossject
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 JBPOS 0101- BioPharm Solutions
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. STATUS EPILEPTICUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. STATUS EPILEPTICUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 STATUS EPILEPTICUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Status Epilepticus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Status Epilepticus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Status Epilepticus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Status Epilepticus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Status Epilepticus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Status Epilepticus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Status Epilepticus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Status Epilepticus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Status Epilepticus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Status Epilepticus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Status Epilepticus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Status Epilepticus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Status Epilepticus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Status Epilepticus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Status Epilepticus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Status Epilepticus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Status Epilepticus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Status Epilepticus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Status Epilepticus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Status Epilepticus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Status Epilepticus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Status Epilepticus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Status Epilepticus - Access and Reimbursement Overview
16 STATUS EPILEPTICUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 STATUS EPILEPTICUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 STATUS EPILEPTICUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 STATUS EPILEPTICUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 STATUS EPILEPTICUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 STATUS EPILEPTICUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 STATUS EPILEPTICUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 STATUS EPILEPTICUS - UNMET NEEDS
10 STATUS EPILEPTICUS - KEY ENDPOINTS OF TREATMENT
11 STATUS EPILEPTICUS - MARKETED PRODUCTS
11.1 List of Status Epilepticus Marketed Drugs Across the Top 7 Markets
11.1.1 Midazolam buccal - Neuraxpharm
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 STATUS EPILEPTICUS - PIPELINE DRUGS
12.1 List of Status Epilepticus Pipeline Drugs Across the Top 7 Markets
12.1.1 Ganaxolone - Marinus Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Midazolam autoinjector - Crossject
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 JBPOS 0101- BioPharm Solutions
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. STATUS EPILEPTICUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. STATUS EPILEPTICUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 STATUS EPILEPTICUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Status Epilepticus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Status Epilepticus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Status Epilepticus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Status Epilepticus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Status Epilepticus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Status Epilepticus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Status Epilepticus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Status Epilepticus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Status Epilepticus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Status Epilepticus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Status Epilepticus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Status Epilepticus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Status Epilepticus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Status Epilepticus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Status Epilepticus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Status Epilepticus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Status Epilepticus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Status Epilepticus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Status Epilepticus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Status Epilepticus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Status Epilepticus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Status Epilepticus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Status Epilepticus - Access and Reimbursement Overview
16 STATUS EPILEPTICUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 STATUS EPILEPTICUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 STATUS EPILEPTICUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
